☆ 4.6 Article

Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates

VIRUSES-BASEL (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, General & Internal

Characteristics, outcomes, and risk factors for in-hospital mortality of COVID-19 patients: A retrospective study in Thailand

Thummaporn Naorungroj et al.

Summary: Limited data on the characteristics and outcomes of hospitalized COVID-19 patients in Thailand were analyzed in this study. The overall mortality rate of hospitalized patients with COVID-19 was 9%, and admission to the ICU was the only factor associated with reduced mortality.

FRONTIERS IN MEDICINE (2023)

添加到收藏夹

Article Immunology

Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019 (COVID-19)

Evan M. Bloch et al.

Summary: This viewpoint provides expert guidance on the use of convalescent plasma for treating immunocompromised patients with COVID-19, including indications, dosage, frequency/schedule, and duration of treatment. English summary rating: 8/10

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Review Hematology

COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research

Lindsey Wang et al.

Summary: This study shows that among the fully vaccinated population, patients with hematologic malignancies (HM) had a significantly higher risk for breakthrough infections compared to patients without cancer. Breakthrough infections in patients with HM were associated with higher rates of hospitalization and mortality.

BLOOD REVIEWS (2022)

添加到收藏夹

Letter Medicine, General & Internal

Admissions in a medical ward and factors independently associated with mortality

Petros Ioannou et al.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2022)

添加到收藏夹

Review Medicine, General & Internal

Risk Factors for Severe COVID-19 in Children: A Systematic Review and Meta-Analysis

Jae Hong Choi et al.

Summary: This study aimed to identify risk factors for severe COVID-19 in children and provide guidance for hospital admission and vaccination priority. The study found that comorbidities such as obesity, diabetes, heart disease, chronic lung diseases, neonates, and premature infants were associated with a higher prevalence of severe COVID-19 in children.

JOURNAL OF KOREAN MEDICAL SCIENCE (2022)

添加到收藏夹

Review Infectious Diseases

Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature

Marcial Delgado-Fernandez et al.

Summary: This article discusses the use of COVID-19 convalescent plasma (CCP) in patients with humoral immunodeficiency. The study suggests that CCP can improve clinical symptoms and shorten the duration of the disease for patients with congenital primary immunodeficiency or those on treatment with anti CD20 antibodies.

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2022)

添加到收藏夹

Article Public, Environmental & Occupational Health

Economic burden of public health care and hospitalisation associated with COVID-19 in China

X. An et al.

Summary: This study evaluates the socio-economic burden imposed on the Chinese healthcare system during the COVID-19 pandemic. The findings highlight the magnitude of resources needed to treat patients with COVID-19 and control the pandemic. The public health measures implemented by the Chinese government have been valuable in reducing the infection rate and may be cost-effective ways to control emerging infectious diseases.

PUBLIC HEALTH (2022)

添加到收藏夹

Article Respiratory System

COVID-19 hospital activity and in-hospital mortality during the first and second waves of the pandemic in England: an observational study

William K. Gray et al.

Summary: The study examined the profile and outcomes of COVID-19 hospitalized patients in England during two waves of the pandemic. There was a significant decline in mortality rates during the early part of the first wave which was largely maintained during the second wave. Some ethnic groups had consistently higher mortality risk.

THORAX (2022)

添加到收藏夹

Article Infectious Diseases

Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases

Oskar Ljungquist et al.

Summary: This study described the clinical and virological treatment outcomes of a group of severely immunosuppressed patients with COVID-19 who received convalescent plasma treatment. Results showed that some patients improved clinically after CCP treatment, but caution should be taken in interpreting the results due to limitations in the study design. Prospective, randomized trials are needed for further investigation.

INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Virology

Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity

Ramona Dolscheid-Pommerich et al.

Summary: This study analyzed the correlation between binding IgG and neutralizing antibodies in COVID-19 patients, revealing a strong positive relationship and supporting the use of QuantiVac ELISA to assess protective immunity post-infection or vaccination.

JOURNAL OF MEDICAL VIROLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Early Outpatient Treatment for Covid-19 with Convalescent Plasma

D. J. Sullivan et al.

Summary: This study evaluated the efficacy and safety of COVID-19 convalescent plasma in symptomatic adults and found that receiving convalescent plasma transfusion reduced the risk of hospitalization due to COVID-19-related reasons.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Immunology

Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies

Zachary A. Yetmar et al.

Summary: Antispike monoclonal antibody treatment showed good outcomes in 180 B-cell-depleted patients with mild-to-moderate COVID-19, with a low progression to severe disease, hospitalization and mechanical ventilation rates, no deaths within 30 days, and a low percentage of persistent COVID-19.

OPEN FORUM INFECTIOUS DISEASES (2022)

添加到收藏夹

Review Health Care Sciences & Services

Economic Burden of COVID-19: A Systematic Review

Fayolah Richards et al.

Summary: This article reviews and synthesizes the evidence on the economic burden of COVID-19, including healthcare resource utilization and costs. The study found that patients with severe COVID-19 were associated with higher costs, mainly driven by ICU admission and in-hospital resource use such as mechanical ventilation. Productivity losses were the most frequently reported indirect costs. Older patients incurred higher costs compared to younger age groups. A Monte Carlo simulation estimated a total direct medical cost of $163.4 billion in the United States based on a 20% COVID-19 infection rate. Preventive measures such as non-pharmaceutical interventions only partially succeeded in reducing the economic costs of the pandemic. Implementing additional measures such as large-scale vaccination is crucial in reducing direct and indirect medical costs, productivity losses, and GDP losses.

CLINICOECONOMICS AND OUTCOMES RESEARCH (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

The genetic and evolutionary determinants of COVID-19 susceptibility

Gaspard Kerner et al.

Summary: This article discusses recent findings on the genetic predisposition of humans to infectious diseases, and explores the disparities between individuals and ethnic groups from an immunological and population genetic perspective. It shows how past genetic adaptation events in human history have contributed to differences in the outcome of SARS-CoV-2 infection and the severity of COVID-19 illness.

EUROPEAN JOURNAL OF HUMAN GENETICS (2022)

添加到收藏夹

Article Medicine, General & Internal

Drug-Drug Interactions among Patients Hospitalized with COVID-19 in Greece

Marios Spanakis et al.

Summary: This study evaluated the prevalence and clinical significance of potential drug-drug interactions (DDIs) in COVID-19 patients admitted to a hospital in Greece. The results showed a high occurrence of DDIs in these patients, with clinically significant DDIs being associated with prolonged hospitalization. The study suggests that healthcare teams should address and resolve the additional burden of DDIs in COVID-19 patients.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Hematology

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Livio Pagano et al.

Summary: Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-SARS-CoV-2 vaccination. This study found a relatively low mortality rate among patients with breakthrough COVID-19, with the Omicron variant being the predominant strain. Patients receiving monoclonal antibody treatment had a lower mortality rate.

BLOOD (2022)

添加到收藏夹

Article Medicine, General & Internal

COVID-19 susceptibility and severity risks in a cross-sectional survey of over 500 000 US adults

Spencer C. Knight et al.

Summary: This study examines the relationship between risk factors and COVID-19 susceptibility and severity, and develops risk models to predict COVID-19 outcomes accurately. The results highlight the value of self-reported epidemiological data in rapidly providing public health insights into the evolving COVID-19 pandemic.

BMJ OPEN (2022)

添加到收藏夹

Review Immunology

COVID-19 in Immunocompromised Hosts: What We Know So Far

Monica Fung et al.

Summary: The COVID-19 pandemic caused by SARS-CoV-2 has led to significant morbidity and mortality globally. The impact of the disease on immunosuppressed patients, such as cancer patients and transplant recipients, remains unclear. Further research is needed to determine the risk of COVID-19 severity and death in immunocompromised patients.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology

Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)

Lindsay Kim et al.

Summary: This study identified factors associated with severe outcomes among adults hospitalized with COVID-19, including age, sex, comorbidities like obesity, immunosuppression, and diabetes. Older age, male gender, and certain underlying conditions were independently linked to increased risk of ICU admission and in-hospital mortality.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology

Treatment of immunocompromised COVID-19 patients with convalescent plasma

Monica Fung et al.

Summary: Convalescent plasma treatment appears to be safe and potentially beneficial for immunosuppressed patients with COVID-19, as evidenced by clinical improvements in patients who received this therapy. Further data is needed to determine the efficacy of convalescent plasma as a primary or adjunctive therapy for COVID-19, especially for immunocompromised patients.

TRANSPLANT INFECTIOUS DISEASE (2021)

添加到收藏夹

Article Surgery

Is COVID-19 infection more severe in kidney transplant recipients?

Sophie Caillard et al.

Summary: Transplant recipients had a higher COVID-19-related mortality compared to nontransplant hospitalized patients but did not differ significantly in the rate of severe disease. Factors associated with severe COVID-19 included age, cardiovascular disease, dyspnea, fever, lymphopenia, and CRP.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

添加到收藏夹

Letter Hematology

Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies

Albrecht Betrains et al.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

R. Libster et al.

Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

V. A. Simonovich et al.

Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Livio Pagano et al.

Summary: This study analyzed baseline characteristics and predictors of mortality in hematological malignancy patients with COVID-19. Results showed that a high percentage of patients developed severe/critical symptoms, with a mortality rate of 31.2%, although improved prevention measures have decreased mortality rates despite an increase in reported cases.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Hematology

Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma

Irati Ormazabal Velez et al.

Summary: The use of convalescent plasma therapy in lymphoma patients with low gammaglobulin levels showed effectiveness in treating relapsed COVID-19, leading to clinical improvement and reducing the risk of virus relapse.

TRANSFUSION AND APHERESIS SCIENCE (2021)

添加到收藏夹

Letter Clinical Neurology

SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort

Zoe L. E. van Kempen et al.

JAMA NEUROLOGY (2021)

添加到收藏夹

Article Hematology

Impact of rituximab on COVID-19 outcomes

Hannah Levavi et al.

Summary: This study examined the impact of prior rituximab therapy on clinical outcomes and antibody development in COVID-19 patients, finding that proximity of the last rituximab infusion to COVID-19 diagnosis did not affect disease severity and mortality rates. Over half of the patients developed neutralizing antibodies, and 11 of the 14 patients with negative antibody titers survived SARS-CoV-2 infection.

ANNALS OF HEMATOLOGY (2021)

添加到收藏夹

Article Immunology

Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products

Ariel Kenig et al.

Summary: This study demonstrates the therapeutic efficacy of convalescent plasma and plasma-based products in a subgroup of immunocompromised patients with iatrogenic B-cell depletion, showing significant clinical improvement and rapid viral clearance following plasma administration.

CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Immunology

Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity

Andreas E. Kremer et al.

Summary: Treatment with convalescent plasma has been shown to be safe in COVID-19 infection, and may boost specific T-cell responses in patients depleted of antibody-producing B cells such as those treated with rituximab.

EUROPEAN JOURNAL OF IMMUNOLOGY (2021)

添加到收藏夹

Article Virology

Post-COVID syndrome: A single-center questionnaire study on 1007 participants recovered from COVID-19

Bircan Kayaaslan et al.

Summary: This study investigated the prevalence and characteristics of post-COVID syndrome among COVID-19 survivors, finding that 47.5% of patients had persistent symptoms, with fatigue, myalgia, and weight loss being the most common. Factors such as severe acute COVID-19, hospitalization, and comorbidities were identified as independent factors for the development of persistent symptoms.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Early Convalescent Plasma for High-Risk Outpatients with Covid-19

Frederick K. Korley et al.

Summary: This study showed that administering Covid-19 convalescent plasma to high-risk outpatients within 1 week after symptom onset did not prevent disease progression.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Rheumatology

Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed

Dimitrios Daoussis et al.

Summary: Research indicates that patients treated with rituximab may have an increased risk of severe, protracted COVID-19 pneumonia. B cell depletion from rituximab treatment may weaken the humoral response against the virus, potentially hindering virus clearance and leading to a prolonged course of the disease. Therefore, delaying rituximab treatment until after COVID-19 vaccination may be a safer option.

RHEUMATOLOGY INTERNATIONAL (2021)

添加到收藏夹

Review Hematology

Use of convalescent plasma in COVID-19 patients with immunosuppression

Jonathon W. Senefeld et al.

Summary: Convalescent plasma therapy may benefit COVID-19 patients with immunosuppression by improving mortality rate and clinical outcomes, but further investigation is needed.

TRANSFUSION (2021)

添加到收藏夹

Article Clinical Neurology

Reactivation of SARS-CoV-2 after Rituximab in a Patient with Multiple Sclerosis

Gauruv Bose et al.

Summary: A 32-year-old woman with highly active MS was infected with SARS-CoV-2 while on treatment with rituximab. She recovered and was symptom-free for 21 days before receiving rituximab and IVIg for comorbid hypogammaglobulinemia, but redeveloped respiratory symptoms three days after the infusion.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

添加到收藏夹

Article Oncology

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19

Michael A. Thompson et al.

Summary: This study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19. Results showed that convalescent plasma treatment was associated with improved 30-day mortality, especially in patients requiring intensive care unit admission or mechanical ventilatory support.

JAMA ONCOLOGY (2021)

添加到收藏夹

Review Medicine, Research & Experimental

Genetic susceptibility of COVID-19: a systematic review of current evidence

SeyedAhmad SeyedAlinaghi et al.

Summary: Through systematic review, evidence has shown a correlation between certain genes, such as ACE2 and TMPRSS2, and the susceptibility to SARS-CoV-2 infection. Additionally, studies have indicated that males are more vulnerable to SARS-CoV-2 infection compared to females, and individuals with the HLA-B*15:03 genotype may have immunity to the virus. Overall, genetic factors play a role in the severity and susceptibility of COVID-19.

EUROPEAN JOURNAL OF MEDICAL RESEARCH (2021)

添加到收藏夹

Article Pathology

Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma

Eric Salazar et al.

AMERICAN JOURNAL OF PATHOLOGY (2020)

添加到收藏夹

Letter Hematology

Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID-19 infected patients

Francesco Lanza et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

添加到收藏夹

Review Medicine, Research & Experimental

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Evan M. Bloch et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

添加到收藏夹

Article Oncology

COVID-19 in persons with haematological cancers

Wenjuan He et al.

LEUKEMIA (2020)

添加到收藏夹

Letter Respiratory System

Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation

Stefano Belli et al.

EUROPEAN RESPIRATORY JOURNAL (2020)

添加到收藏夹

Letter Hematology

Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery

Evangeline Clark et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Early safety indicators of COVID-19 convalescent plasma in 5000 patients

Michael J. Joyner et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients

Michael J. Joyner et al.

MAYO CLINIC PROCEEDINGS (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Disease and healthcare burden of COVID-19 in the United States

Ian F. Miller et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Rheumatology

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study

Jesus Loarce-Martos et al.

RHEUMATOLOGY INTERNATIONAL (2020)

添加到收藏夹

Review Oncology

COVID-19 in cancer patients: risk, clinical features, and management

Cuiwei Liu et al.

CANCER BIOLOGY & MEDICINE (2020)

添加到收藏夹

Review Immunology

B cell targeted therapies in autoimmune disease

Jennifer L. Barnas et al.

CURRENT OPINION IN IMMUNOLOGY (2019)

添加到收藏夹

Review Immunology

Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution

Keith A. Sacco et al.

IMMUNOTHERAPY (2018)

添加到收藏夹

Review Oncology

Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma

Sohita Dhillon

TARGETED ONCOLOGY (2017)

添加到收藏夹

Review Medicine, Research & Experimental

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

Gilles Salles et al.

ADVANCES IN THERAPY (2017)

添加到收藏夹

Review Urology & Nephrology

B-cell depletion in the treatment of lupus nephritis

Jon W. Gregersen et al.

NATURE REVIEWS NEPHROLOGY (2012)

添加到收藏夹

Review Immunology

The role of B lymphocytes as antigen-presenting cells

Xinjian Chen et al.

ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2008)

添加到收藏夹

Article Medicine, General & Internal

B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis

Stephen L. Hauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹

Review Biochemistry & Molecular Biology

B cell depletion therapy in autoimmune diseases

Inaki Sanz et al.

FRONTIERS IN BIOSCIENCE-LANDMARK (2007)

添加到收藏夹

Review Medicine, General & Internal

Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment?

Thomas C. Luke et al.

ANNALS OF INTERNAL MEDICINE (2006)

添加到收藏夹

Article Hematology

Risks and side effects of therapy with plasma and plasma fractions

S MacLennan et al.

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2006)

添加到收藏夹

Article Infectious Diseases

Use of convalescent plasma therapy in SARS patients in Hong Kong

Y Cheng et al.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.